Advanced

Complement inhibitor C4b-binding protein in primary Sjögren's syndrome and its association with other disease markers.

Foltyn Zadura, Anna LU ; Theander, Elke LU ; Blom, Anna LU and Trouw, Leendert LU (2009) In Scandinavian Journal of Immunology 69(4). p.374-380
Abstract
A subgroup of patients suffering from primary Sjögren's syndrome (pSS) display unexplained low levels of complement components C3 and/or C4 which is associated with increased risk of non-Hodgkin's lymphoma. C4b-binding protein (C4BP) is a major fluid-phase complement inhibitor which can influence C4 and C3 levels. Therefore we analysed C4BP levels in the sera of patients with pSS to better understand the disturbances in complement in pSS. Associations with other disease markers were also investigated to define a possible role of C4BP as marker of high-risk disease course. Plasma levels of C4BP were analysed in pSS patients (n=86) and in controls (n=68) by ELISA. C4BP levels from 49 patients were correlated to disease activity markers and... (More)
A subgroup of patients suffering from primary Sjögren's syndrome (pSS) display unexplained low levels of complement components C3 and/or C4 which is associated with increased risk of non-Hodgkin's lymphoma. C4b-binding protein (C4BP) is a major fluid-phase complement inhibitor which can influence C4 and C3 levels. Therefore we analysed C4BP levels in the sera of patients with pSS to better understand the disturbances in complement in pSS. Associations with other disease markers were also investigated to define a possible role of C4BP as marker of high-risk disease course. Plasma levels of C4BP were analysed in pSS patients (n=86) and in controls (n=68) by ELISA. C4BP levels from 49 patients were correlated to disease activity markers and autoantibody profiles. We found that total C4BP plasma levels were significantly higher in pSS patients compared with controls. C4BP levels correlated to the acute phase response, to levels of C4 and C3 as well as to the CD4+/CD8+ T-cell ratio. C4BP levels were inversely related to IgG levels, extent of autoantibody production and global disease activity. C3dg levels, a marker of complement activation, displayed a negative correlation to C4 levels but interestingly not to C4BP levels. In conclusion, C4BP levels are increased in patients suffering from pSS proportional to their acute phase response. However, in the most active cases, with the most widespread autoantibody production, C4BP levels were decreased in parallel with levels of C3 and C4 and CD4+ T cells, suggesting that disturbed complement regulation may contribute to pathogenicity in pSS. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scandinavian Journal of Immunology
volume
69
issue
4
pages
374 - 380
publisher
Wiley-Blackwell
external identifiers
  • WOS:000263911100012
  • PMID:19284503
  • Scopus:61849088306
ISSN
1365-3083
DOI
10.1111/j.1365-3083.2009.02229.x
language
English
LU publication?
yes
id
dac89d2c-6fdf-4a67-a79a-a1747f435a89 (old id 1367826)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19284503?dopt=Abstract
date added to LUP
2009-04-08 11:51:06
date last changed
2016-10-13 04:32:57
@misc{dac89d2c-6fdf-4a67-a79a-a1747f435a89,
  abstract     = {A subgroup of patients suffering from primary Sjögren's syndrome (pSS) display unexplained low levels of complement components C3 and/or C4 which is associated with increased risk of non-Hodgkin's lymphoma. C4b-binding protein (C4BP) is a major fluid-phase complement inhibitor which can influence C4 and C3 levels. Therefore we analysed C4BP levels in the sera of patients with pSS to better understand the disturbances in complement in pSS. Associations with other disease markers were also investigated to define a possible role of C4BP as marker of high-risk disease course. Plasma levels of C4BP were analysed in pSS patients (n=86) and in controls (n=68) by ELISA. C4BP levels from 49 patients were correlated to disease activity markers and autoantibody profiles. We found that total C4BP plasma levels were significantly higher in pSS patients compared with controls. C4BP levels correlated to the acute phase response, to levels of C4 and C3 as well as to the CD4+/CD8+ T-cell ratio. C4BP levels were inversely related to IgG levels, extent of autoantibody production and global disease activity. C3dg levels, a marker of complement activation, displayed a negative correlation to C4 levels but interestingly not to C4BP levels. In conclusion, C4BP levels are increased in patients suffering from pSS proportional to their acute phase response. However, in the most active cases, with the most widespread autoantibody production, C4BP levels were decreased in parallel with levels of C3 and C4 and CD4+ T cells, suggesting that disturbed complement regulation may contribute to pathogenicity in pSS.},
  author       = {Foltyn Zadura, Anna and Theander, Elke and Blom, Anna and Trouw, Leendert},
  issn         = {1365-3083},
  language     = {eng},
  number       = {4},
  pages        = {374--380},
  publisher    = {ARRAY(0x9885278)},
  series       = {Scandinavian Journal of Immunology},
  title        = {Complement inhibitor C4b-binding protein in primary Sjögren's syndrome and its association with other disease markers.},
  url          = {http://dx.doi.org/10.1111/j.1365-3083.2009.02229.x},
  volume       = {69},
  year         = {2009},
}